Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toby M Maher

Showing results (171-180 of 391) with videos related to

Pageof 40
Sort By:
Thorax|October 16, 2012
The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health statusAmit Suresh Patel, Richard J Siegert, Daniel Creamer, et al.
ERJ Open Research|July 30, 2024
Modified blood cell GAP model as a prognostic biomarker in idiopathic pulmonary fibrosisMichael Kreuter, Joyce S Lee, Argyrios Tzouvelekis, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 3, 2020
Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled TrialToby M Maher, Maureen D Mayes, Michael Kreuter, et al.
BMJ Open Respiratory Research|April 9, 2019
The King's Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important differenceAish Sinha, Amit Suresh Patel, Richard J Siegert, et al.
ERJ Open Research|August 6, 2024
A comparison of respiratory oscillometry and spirometry in idiopathic pulmonary fibrosis: performance time, symptom burden and test-retest reliabilitySuhani Patel, Karl P Sylvester, Zhe Wu, et al.
ERJ Open Research|July 23, 2024
Circulating biomarkers and progression of idiopathic pulmonary fibrosis: data from the INMARK trialToby M Maher, R Gisli Jenkins, Vincent Cottin, et al.
The European Respiratory Journal|November 17, 2018
The potential impact of azithromycin in idiopathic pulmonary fibrosisClaudio Macaluso, Joaquín Maritano Furcada, Omamah Alzaher, et al.
BMJ Open Respiratory Research|June 11, 2019
Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)Toby M Maher, Michael Kreuter, David J Lederer, et al.
The Lancet. Respiratory Medicine|April 7, 2016
Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysisMichael Kreuter, Wim Wuyts, Elisabetta Renzoni, et al.
The Lancet. Respiratory Medicine|September 7, 2016
Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution - Authors' replyMichael Kreuter, Wim Wuyts, Elisabetta Renzoni, et al.
Pageof 40

Showing results (171-180 of 391) with videos related to

Sort By:
Pageof 40
Thorax|October 16, 2012
The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health statusAmit Suresh Patel, Richard J Siegert, Daniel Creamer, et al.
ERJ Open Research|July 30, 2024
Modified blood cell GAP model as a prognostic biomarker in idiopathic pulmonary fibrosisMichael Kreuter, Joyce S Lee, Argyrios Tzouvelekis, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 3, 2020
Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled TrialToby M Maher, Maureen D Mayes, Michael Kreuter, et al.
BMJ Open Respiratory Research|April 9, 2019
The King's Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important differenceAish Sinha, Amit Suresh Patel, Richard J Siegert, et al.
ERJ Open Research|August 6, 2024
A comparison of respiratory oscillometry and spirometry in idiopathic pulmonary fibrosis: performance time, symptom burden and test-retest reliabilitySuhani Patel, Karl P Sylvester, Zhe Wu, et al.
ERJ Open Research|July 23, 2024
Circulating biomarkers and progression of idiopathic pulmonary fibrosis: data from the INMARK trialToby M Maher, R Gisli Jenkins, Vincent Cottin, et al.
The European Respiratory Journal|November 17, 2018
The potential impact of azithromycin in idiopathic pulmonary fibrosisClaudio Macaluso, Joaquín Maritano Furcada, Omamah Alzaher, et al.
BMJ Open Respiratory Research|June 11, 2019
Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)Toby M Maher, Michael Kreuter, David J Lederer, et al.
The Lancet. Respiratory Medicine|April 7, 2016
Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysisMichael Kreuter, Wim Wuyts, Elisabetta Renzoni, et al.
The Lancet. Respiratory Medicine|September 7, 2016
Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution - Authors' replyMichael Kreuter, Wim Wuyts, Elisabetta Renzoni, et al.
Pageof 40